Biclonal origin prevails in concomitant chronic lymphocytic leukemia and multiple myeloma

Pantić, Milena; Schroettner, Percy; Pfeifer, Dietmar; Rawluk, Justyna; Denz, Ulrich; Schmitt‐Gräff, Annette; Veelken, Hendrik; Wäsch, Ralph; Engelhardt, Monika

doi:10.1038/leu.2009.294

Cited by 36 publications

(37 citation statements)

References 14 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In all deceased patients, follow-up information was meticulously obtained as described. 9,12,14,15 All 744 patients included in this analysis were treated at our institution between January 1997 and December 2011. The median follow up was 89 months, with long-term follow up of second cancers and death from myeloma being available for 25 years.…”

Section: Patients' Characteristics and Data Sourcementioning

confidence: 99%

“…Mobilization (IEV) and conditioning (melphalan 200 mg/m 2 ) were performed as described. 1,12,14,15 Patients ineligible for ASCT received either bortezomib, melphalan, prednisone (VMP) or melphalan, prednisone, thalidomide (MPT). Relapse treatment consisted of standard anti-myeloma/novel agent combinations, containing lenalidomide, thalidomide and bortezomib (RD, VRD, VCD).…”

Section: Treatmentmentioning

confidence: 99%

“…10,12,14,15 The analysis was carried out in accordance with the Declaration of Helsinki and according to Good Clinical Practice Guidelines. All patients gave their written informed consent for institutional-initiated research studies and analyses of clinical outcome studies, conforming with our institutional review board guidelines.…”

Section: Patients' Characteristics and Data Sourcementioning

confidence: 99%

“…Diagnosis of mature B-cell neoplasms was staged according to the Rai classification. 9,12,14 Primary myeloma was defined as diagnosis of myeloma at least three months prior to diagnosis of another malignancy. Secondary myeloma was defined with an onset longer than three months after diagnosis of a prior malignancy.…”

Section: Disease Classificationmentioning

confidence: 99%

See 3 more Smart Citations

Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years

et al. 2015

View full text Add to dashboard Cite

Section: Patients' Characteristics and Data Sourcementioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Section: Patients' Characteristics and Data Sourcementioning

confidence: 99%

Section: Disease Classificationmentioning

confidence: 99%

See 2 more Smart Citations

Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years

et al. 2015

View full text Add to dashboard Cite

“…In few instances, a derivation from a single B-cell precursor has been suggested by the demonstration of identical IgH gene rearrangements, but opposite results were found in most cases and biclonal origin prevails. 25 Interesting epidemiologic studies carried out in the past Fig. 7.…”

Section: Discussionmentioning

confidence: 99%

Simultaneous Presentation of Waldenstr^|^ouml;m Macroglobulinemia and Multiple Myeloma: Multidisciplinary Diagnosis, Treatment and 30-Month Follow-up

Carulli

Ciancia

Azzarà

et al. 2013

J Clin Exp Hematopathol

View full text Add to dashboard Cite

Waldenström macroglobulinemia and multiple myeloma are mature B-cell neoplasms deriving from post-germinal cells at different stages of differentiation. The simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma in the same patient is a very rare phenomenon and, so far, only two cases have been described. We report the case of a 75-year Caucasian female patient, with a silent clinical history, who presented with anemia and two different monoclonal proteins (IgMk and IgGk). The trephine biopsy showed the presence of a dual population, represented by small lymphoplasmacytoid cells and by plasma cells, which infiltrated the bone marrow with a clearly different pattern. Both immunohistochemistry and flow cytometry demonstrated the biclonal origin such neoplastic cells, since lymphoplasmacytoid cells resulted IgMk while plasma cells were IgGk. This biclonal pattern was further confirmed by the demonstration of a different IgH gene rearrangement of the two neoplasms. The patient was treated with bortezomib, dexamethasone and rituximab, achieving partial remission of both Waldenström macroglobulinemia and multiple myeloma. After a 30-month follow-up, she is in stable disease. Multiple myeloma has been described in association with other indolent B-cell neoplasms, mostly chronic lymphocytic leukemia, while Waldenström macroglobulinemia can be followed by diffuse large B-cell lymphoma in some instances, after chemotherapy. The association of Waldenström macroglobulinemia and multiple myeloma seems to be very rare. Our study shows that an integrated diagnostic work-up is very useful in such cases, with an interesting role for flow cytometry. 〔J Clin Exp Hematop 53(1): 29-36, 2013〕

show abstract

Coexistence of chronic lymphocytic leukemia and multiple myeloma, do the roots of these entities originate from the same place?

Merdin

Yıldız

Dal

et al. 2017

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Biclonal origin prevails in concomitant chronic lymphocytic leukemia and multiple myeloma

Cited by 36 publications

References 14 publications

Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years

Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years

Simultaneous Presentation of Waldenstr^|^ouml;m Macroglobulinemia and Multiple Myeloma: Multidisciplinary Diagnosis, Treatment and 30-Month Follow-up

Coexistence of chronic lymphocytic leukemia and multiple myeloma, do the roots of these entities originate from the same place?

Contact Info

Product

Resources

About